This original manuscript depicts the beneficial effects, and underlying mechanisms, of the pan-ppar agonist lanifibranor on portal hypertension and liver fibrosis in advanced chronic liver disease.
This original study demonstrates that a nutraceutical rich in DHA significantly improves portal hypertension in chronic liver disease mainly by suppressing inflammation and oxidative stress-driven hepatic stellate cell activation, encouraging its evaluation as a new treatment for portal hypertension and cirrhosis.
This study defines BLB’s BarNa model: a pre-clinical model of moderate and advanced NASH that mimics the human disease, including pathophysiologic characteristics and transcriptomic signature. Read the entire work.
This study demonstrates that emricasan improves liver sinusoidal microvascular dysfunction in cirrhosis, which leads to marked amelioration in fibrosis, portal hypertension and liver function, in pre-clinical models of advanced cirrhosis.
This original manuscript describes a new bioengineered device that mimics the human sinusoid in vitro, representing a novel method to study liver diseases and toxicology. The unique and BLB’s proprietary ExoLiver platform.
This study demonstrates for the first time that liraglutide improves the liver sinusoidal milieu in pre-clinical models of cirrhosis, provides mechanistic insight, and altogether encourages the clinical evaluation of GLP-1 receptor agonists for the treatment of chronic liver disease.